NCT07201714 Oral Carnitine in Heart Failure Patients
| NCT ID | NCT07201714 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-12 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2025-11-12 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.
Eligibility Criteria
Inclusion Criteria: * Clinical-pathological diagnosis of heart failure with some degree of cardiorenal syndrome * Stage 1, 2, 3a, 3b, or 4 chronic kidney disease * Age ≥ 18 years * Able to speak and read English * Willing and able to provide consent Exclusion Criteria: * Estimated GFR \<15 mL/min/1.73m2 or Stage 5 chronic kidney disease * Currently undergoing renal replacement therapy of any kind * Pregnant, breastfeeding or intending pregnancy * History of seizures of any type * Known allergy to levocarnitine, magnesium stearate, microcrystalline cellulose or povidone * Unable to provide consent
Contact & Investigator
Chris McIntyre, MBBS DM
PRINCIPAL INVESTIGATOR
London Health Sciences Centre
Frequently Asked Questions
Who can join the NCT07201714 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07201714 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07201714 currently recruiting?
Yes, NCT07201714 is actively recruiting participants. Contact the research team at kathleen.koyle@lhsc.on.ca for enrollment information.
Where is the NCT07201714 trial being conducted?
This trial is being conducted at London, Canada.
Who is sponsoring the NCT07201714 clinical trial?
NCT07201714 is sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. The principal investigator is Chris McIntyre, MBBS DM at London Health Sciences Centre. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.